On March 16, 2026, Agenus Inc. announced its financial results for the fourth quarter and full year ended December 31, 2025. The company highlighted significant progress in its botensilimab (BOT) plus balstilimab (BAL) immunotherapy program, which is now entering global Phase 3 evaluation in refractory microsatellite-stable (MSS) metastatic colorectal cancer (mCRC). This combination therapy has shown promising results, with a reported 42% two-year overall survival rate in heavily pretreated patients. Additionally, the company recognized approximately $4.2 million in initial revenue from early access programs across more than 30 countries, indicating strong interest from physicians and patients alike. The expansion of early access programs in France, which now includes metastatic ovarian cancer and sarcoma, further underscores the growing demand for this innovative treatment. The strategic collaboration with Zydus Lifesciences has also strengthened Agenus' balance sheet and manufacturing capabilities, positioning the company for future growth and commercialization efforts. With these developments, Agenus is optimistic about the potential of BOT+BAL to become a leading immunotherapy option for patients with difficult-to-treat cancers.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.